Matches in Nanopublications for { ?s ?p "[Using immunohistochemistry, a score including PAK1 and co-expression of PKA and ER?S305-P (PKA/ER?S305-P) was developed on a training set consisting of 103 patients treated with tamoxifen for metastatic disease, and validated on 231 patients randomized between adjuvant tamoxifen or no treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP841033.RAiFRvlFKNIaTFO6Q2kdZIuUPx_GrUUdjf4mRQ-gurHmk130_assertion description "[Using immunohistochemistry, a score including PAK1 and co-expression of PKA and ER?S305-P (PKA/ER?S305-P) was developed on a training set consisting of 103 patients treated with tamoxifen for metastatic disease, and validated on 231 patients randomized between adjuvant tamoxifen or no treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP841033.RAiFRvlFKNIaTFO6Q2kdZIuUPx_GrUUdjf4mRQ-gurHmk130_provenance.
- NP176941.RAMbPGpx0gvV9SB4o9dbCIm5YqLh1XUJCAP-8ZFKx_flM130_assertion description "[Using immunohistochemistry, a score including PAK1 and co-expression of PKA and ER?S305-P (PKA/ER?S305-P) was developed on a training set consisting of 103 patients treated with tamoxifen for metastatic disease, and validated on 231 patients randomized between adjuvant tamoxifen or no treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP176941.RAMbPGpx0gvV9SB4o9dbCIm5YqLh1XUJCAP-8ZFKx_flM130_provenance.
- NP608081.RAV32F96Q8FlrE2sIlWxWDdIv2iqWOYxTP-vI6XEQMCbI130_assertion description "[Using immunohistochemistry, a score including PAK1 and co-expression of PKA and ER?S305-P (PKA/ER?S305-P) was developed on a training set consisting of 103 patients treated with tamoxifen for metastatic disease, and validated on 231 patients randomized between adjuvant tamoxifen or no treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP608081.RAV32F96Q8FlrE2sIlWxWDdIv2iqWOYxTP-vI6XEQMCbI130_provenance.
- NP608193.RARiDH4SPNJOCcl-mc4DXHRleK-TQ4KpS73Q0E3DhZzpI130_assertion description "[Using immunohistochemistry, a score including PAK1 and co-expression of PKA and ER?S305-P (PKA/ER?S305-P) was developed on a training set consisting of 103 patients treated with tamoxifen for metastatic disease, and validated on 231 patients randomized between adjuvant tamoxifen or no treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP608193.RARiDH4SPNJOCcl-mc4DXHRleK-TQ4KpS73Q0E3DhZzpI130_provenance.
- assertion description "[Using immunohistochemistry, a score including PAK1 and co-expression of PKA and ER?S305-P (PKA/ER?S305-P) was developed on a training set consisting of 103 patients treated with tamoxifen for metastatic disease, and validated on 231 patients randomized between adjuvant tamoxifen or no treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP798590.RAYArXCBT3sbprhhu_Yaqa2VcmqvUKSnw2SPzd3mcHTqM130_assertion description "[Using immunohistochemistry, a score including PAK1 and co-expression of PKA and ER?S305-P (PKA/ER?S305-P) was developed on a training set consisting of 103 patients treated with tamoxifen for metastatic disease, and validated on 231 patients randomized between adjuvant tamoxifen or no treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP798590.RAYArXCBT3sbprhhu_Yaqa2VcmqvUKSnw2SPzd3mcHTqM130_provenance.